 |
市場調查報告書
泰黴素的全球市場:2020-2027年Global Tylosin Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 965968 | ||||
| 出版日期 | 按訂單生產 | 內容資訊 | 英文 商品交期: 請詢問到貨日 |
||||
| 價格 |
|
||||||
| 泰黴素的全球市場:2020-2027年 Global Tylosin Market - 2020-2027 | ||
| 出版日期: 按訂單生產 | 內容資訊: 英文 |
|
全球泰黴素市場成長，由於畜產業對泰黴素的需求高漲受到推動。畜牧業對泰樂菌素的需求不斷成長，帶動了全球泰樂菌素市場的成長。新興經濟體收入水平上升和可支配收入增加，使得需求增加。反之，預計牲畜抗菌素耐藥性增加將在預測期內限制全球泰樂菌素市場的成長。
本報告提供全球泰黴素市場相關調查，市場概要，各市場區隔及各地區的市場規模的預測，主要企業的簡介，競爭情形分析等系統性資訊。
The global tylosin market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Tylosin is an antibiotic of the macrolide class developed for veterinary use. It is made naturally by the bacterium Streptomyces fradiae and acts to inhibit bacterial protein synthesis by inhibiting the 50S ribosome, a cellular structure only certain bacteria have and use to make internal proteins. Tylosin is licensed for use as a broad spectrum antibiotic for injectable or oral use in treatment of infection such as respiratory tract and skin infections in livestock. In small animals, tylosin has been used for its anti-inflammatory and antibiotic properties to treat colitis. It may also be used as a growth promoter in food animals. These factors are driving the growth of the market in the forecast period.
The global tylosin market growth is driven by the rising demand for tylosin in livestock industry. Tylosin is used for treatment and control of swine dysentery associated with Brachyspira Hyodysenteriae and for the control of porcine proliferate enteropathies in pigs. Moreover, Tylosin is highly effective in tylosin-responsive diarrhea in dogs, which is a canine chronic, recurrent diarrhea that responds repeatedly to Tylosin treatment.
Increasing demand for tylosin in livestock industry is expected to propel growth
The global Tylosin market is expected to witness significant growth over the forecast period, owing to rising demand for tylosin in livestock industry. For instance, according to a study by Ministry for Primary Industries, New Zealand 2016, Tylosin accounted for over 83% of macrolide and lincosamide sales during 2011 and 2014 and the trend is expected to continue over the forecast period.
Antimicrobial medications are generally used in the livestock industry for treatment of various infections in the livestock, prevention of disease, and to improve growth rate of the animals efficiency. Moreover, antimicrobial medications have been found to be effective in animals for improving growth rate and increasing weight more efficiently, which in turn results in increasing profits for the meat producers.
Rising income levels and disposable income in emerging economies increase in demand
Rising income levels and disposable income in emerging economies such as Asia-Pacific has caused increase in demand for healthy protein sources for consumption as daily protein need of the body is not met through conventional food sources. According to NCBI, 2015, in Asia, the daily animal protein intake increased from 7 grams per capita per day to 25 grams per capita per day between 1960, and 2013. Countries such as Brazil, Russia, India, China, and South Africa (BRICS) have started implementing intensive livestock production systems to meet this demand (which necessitates use of antimicrobials). These factors are expected to support growth of the global Tylosin market over the forecast period.
Increasing antimicrobial resistance in livestock is expected to restrain market growth
On the contrary, increasing antimicrobial resistance in livestock is expected to restrain growth of the global Tylosin market over the forecast period. For instance, in 2013, University of California, San Francisco (UCSF) Academic Senate passed a resolution to restrict purchase of meat raised with nontherapeutic antibiotics. This factor restrain the market growth of tylosin in the forecast period.
The potential side effects associated with its use will hamper its market growth
The most common side effects of tylosin use include pain and inflammation at the injection site and mild gastrointestinal upset, such as decreased appetite and diarrhea. This short-acting medication should stop working within 24 hours, although effects can be longer in pets with liver or kidney disease.
COVID-19 Impact Analysis
The effects of COVID-19 on the livestock medications are still largely unquantified and yet to be fully felt. Movement restrictions and illness are resulting in tylosin shortages and reduced supply of raw materials or other API to its production. Disruption of supply routes has further delayed its supply. In China the world's biggest tylosin exporter restrictions have reduced its production in the factories by half, which could affect global trade flows. Thus, the pandemic has decreased the sale which hamper the global tylosin market in the forecast period.
By drug type, the tylosin market is classified into tylosin phosphate, tylosin tartrate, tylosin base, and others
Tylosin Tartrate segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Tylosin tartrate is a particular type of antibiotic that is commonly used in a variety of animals, including dogs, cats, cattle, horses and more. This antibiotic serves a wide range of different purposes, but like other antibiotics it is designed specifically to target and kill certain types of bacteria. Without treating these bacteria, your pet may run the risk of developing an infection. In terms of its effects on animals. In dogs, tylosin tartrate is most commonly used to treat both gastric infections in general and colitis in particular. Colitis, which is characterized by irritable bowels and a lack of proper consistency in bowel movements, as well as excessive flatulence and general stomach upset, is caused by an influx of harmful bacteria in the gut and digestive tract. Regular treatments of tylosin tartrate have been shown to help eliminate this bacteria, particularly in smaller animals.
The demand for livestock animals for consumption is on the rise worldwide and is expected to maintain the positive growth in demand over the forecast period. Subsequently, the demand for infection-free and healthy livestock used primarily for consumption is increasing. However, the prevalence of various microbial infections is high in both humans and animals. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, zoonotic diseases are common in the U.S. and worldwide and over 6 out of every 10 known infectious diseases in humans are spread from animals. Hence, antibiotics are an important medication for livestock that aide in providing healthy food products for consumption in humans. This factor is driving the growth of the segment in the forecast period.
On the basis of application, the tylosin market is classified into felines, canines, and livestock.
The livestock are expected to dominate the tylosin market during the forecast period
The major factors responsible for the growth of this segment include the efficiency of tylosin in various diseases or conditions, such as chronic respiratory disease (CRD) associated with Mycoplasma Gallisepticum and Mycolplasma synoviae and other infections.
According to National Center for Biotechnology Information (NCBI), 2015, around 80% of antibiotics sold in the U.S. are for livestock and almost 70% of these are medically important. Moreover, according to NCBI, the antimicrobial consumption in livestock is expected to increase by 67% by 2030, and nearly double. These factors are expected to boost the global Tylosin market growth over the forecast period.
Moreover, antibiotics such as tylosin are used in various animal species for prevention of mycoplasmosis. For instance, animals such as chickens, turkeys, pigs, and calves require oral Tylosin to be administered in required dosage to prevent mycoplasmosis and to grow healthy livestock. Furthermore, livestock is a major source of income in several of the emerging economies such as Brazil, which is major factor expected to contribute in growth of the market in the region over the forecast period.
Geographical Analysis
North America region holds the largest market share global tylosin market
North America region is dominating the global tylosin market accounted for the largest market share in 2019, owing to a wide range of definitive measures adopted by government animal welfare organizations that are consistently working for overall improvement in animal health.
Apart from the high prevalence of GI disorders, the changing lifestyle, unhealthy eating habits, and high disposable income are contributing to the high growth rates. On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period. Furthermore, technological advancements, rising incidence of zoonotic diseases, and increasing number of pet owners are expected to boost the market in this country. Collaborative efforts undertaken by major companies to enhance their R&D capabilities and ensure high quality standards are also anticipated to impel demand across this region. Also, the steady importance given to agricultural contribution to these countries makes the owner more responsible for better care of farm animals. The healthcare expenditure compared to other countries, also fuels the market growth in North America. Thus, it should hold a major share of the market, over the forecast period.
Asia Pacific is expected to register a positive growth in the forecast period. The high growth registered by this region is believed to be a consequence of consistent R&D investments by prominent players in the field of animal health and their efforts to commercialize at a relatively inexpensive price of tylosin.
The tylosin market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, Elanco Animal Health, Apeloa Kangyu and Top Pharm Chemical Group among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the tylosin market globally.
Elanco Animal Health
Overview: Elanco Animal Health Incorporated operates as an animal health care company. The Company develops, manufactures, and markets products for companion and food animals. Elanco Animal Health serves clients worldwide. Elanco Animal Health is located in BASINGSTOKE, United Kingdom and is part of the Pharmaceutical Manufacturing Industry. Elanco Animal Health has 49 employees at this location and generates $8.66 million in sales (USD).
Product Portfolio: The Company's portfolio comprised of Farm Animal Products & Services, Pet Animal Products & Services, and Care4Pigs.
The global tylosin market report would provide an access to an approx. 60 market data table, 52 figures and 250 pages.
LIST NOT EXHAUSTIVE
